Ionis said the U.S. FDA approved a wider label for Tryngolza (olezarsen), expanding the drug’s use to a broader set of patients with severe hypertriglyceridemia and related risk of pancreatitis. The approval follows earlier clinical results and unlocks a larger commercial opportunity for Ionis beyond its initial, narrower population. With the new FDA nod, Tryngolza moves further from an ultra-focused indication set into a more prevalent cardiometabolic market. Ionis framed the change as part of its broader shift toward developing and commercializing assets internally rather than relying on partnerships. In related coverage, Ionis also indicated its Tryngolza program has already benefited from priority review and breakthrough therapy designations, underscoring regulators’ interest in the antisense approach. Why it matters: label expansion changes patient-identification pathways, payer strategies, and competitive positioning in severe hypertriglyceridemia—an area with well-defined outcomes tied to pancreatitis risk.